Page 158 - 南京医科大学自然版

第45卷第5期
·744 · 南 京 医 科 大 学 学 报 2025年5月

［45］CAMARD M，BESSE B，CARIOU P L，et al. Prevalence ［52］PAN L，MENG F Q，WANG W，et al. Nintedanib in an
and outcome of steroid ⁃ resistant/refractory pneumonitis elderly non ⁃ small ⁃ cell lung cancer patient with severe
induced by immune checkpoint inhibitors［J］. Respir steroid⁃refractory checkpoint inhibitor⁃related pneumoni⁃
Med Res，2022，82：100969 tis：a case report and literature review［J］. Front Immunol，
［46］OGUSU S，HARUTANI Y，TOZUKA T，et al. Second⁃line 2023，13：1072612
immunosuppressant administration for steroid ⁃ refractory ［53］ DOLLADILLE C，EDERHY S，SASSIER M，et al. Im⁃
immune⁃related adverse events in patients with lung can⁃ mune checkpoint inhibitor rechallenge after immune ⁃
cer［J］. Cancer Immunol Immunother，2023，72（11）： related adverse events in patients with cancer［J］. JAMA
3765-3772 Oncol，2020，6（6）：865-871
［47］STROUD C R，HEGDE A，CHERRY C，et al. Tocilizumab ［54］LIN X Q，DENG H Y，CHU T Q，et al. Safety and efficacy
for the management of immune mediated adverse events of immunotherapy rechallenge following checkpoint inhib⁃
secondary to PD ⁃ 1 blockade［J］. J Oncol Pharm Pract， itor⁃related pneumonitis in advanced lung cancer patients：
2019，25（3）：551-557 a retrospective multi⁃center cohort study［J］. Transl Lung
［48］ZHAI X Y，ZHANG J，TIAN Y R，et al. The mechanism Cancer Res，2022，11（11）：2289-2305
and risk factors for immune checkpoint inhibitor pneumo⁃ ［55］ BYLSMA S，YUN K R，PATEL S，et al. Immune check⁃
nitis in non⁃small cell lung cancer patients［J］. Cancer Bi⁃ point inhibitor rechallenge after prior immune toxicity［J］.
ol Med，2020，17（3）：599-611 Curr Treat Options Oncol，2022，23（9）：1153-1168
［49］ LAI K C，HSIAO Y H，CHEN S C. Pulse corticosteroid ［56］ZHAO Q，ZHANG J W，XU L Y，et al. Safety and efficacy
therapy in the treatment of steroid ⁃ refractory immune of the rechallenge of immune checkpoint inhibitors after
checkpoint inhibitor ⁃ related pneumonitis：Case report immune⁃related adverse events in patients with cancer：a
and review［J］. Front Immunol，2022，13：994064 systemic review and meta ⁃ analysis［J］. Front Immunol，
［50］UTSUMI H，ARAYA J，OKUDA K，et al. Successful treat⁃ 2021，12：730320
ment of steroid⁃refractory immune checkpoint inhibitor⁃re⁃ ［57］ ALLOUCHERY M，LOMBARD T，MARTIN M，et al.
lated pneumonitis with triple combination therapy：a case Safety of immune checkpoint inhibitor rechallenge after
report［J］. Cancer Immunol Immunother，2020，69（10）： discontinuation for grade ≥2 immune ⁃ related adverse
2033-2039 events in patients with cancer［J］. J Immunother Cancer，
［51］MIAO K，XU Y，XU W S，et al. Treatment of steroid⁃resis⁃ 2020，8（2）：e001622
tant checkpoint inhibitor pneumonitis with pirfenidone：a ［收稿日期］ 2024-12-15
case report［J］. Thorac Cancer，2021，12（15）：2214-2216 （本文编辑：蒋 莉）